# Striving to become China's leading semiconductor equipment manufacturer via the acquisition of NMC

### 22 Mar 2016

# **Investment Highlights**

- Private placement to fund acquisition of China's premium \* semiconductor equipment manufacturer - Beijing NMC. As the only A-share listed semiconductor equipment manufacturer, Sevenstar is China's leading player in the production of oxidation furnaces and wafer cleaning systems. Sevenstar plans to fully acquire Beijing North Microelectronics (China's leading player in silicon etching and PVD equipment) from its parent (Beijing Electronics Holding). The deal is priced at 14.6x 2016 earnings and Sevenstar plans to fund the acquisition with an Rmb924mn share placement (issuing 52.81mn new shares priced at Rmb17.49/share). As part of the deal, NMC is committed to 2016 net profit of Rmb63.17mn and revenue of Rmb510/660/840mn over 2016-18. In addition, Sevenstar is looking to raise a further Rmb924mn from three institutional investors in a separate private placement, to fund NMC's capacity expansion project. Upon completion of the deals, Sevenstar's share capital would have increased by 30%.
- Domestic companies facing both challenges and opportunities in a \* semiconductor market with massive potential. Due to a number of factors including: (i) high technological barriers and market concentration; (ii) protracted R&D cycle; as well as (iii) technology transfer embargo put in place jointly by developed nations, Japan and the US have five and four companies ranked amongst the top-10 semiconductor equipment manufacturers worldwide. Meanwhile, the top-4 companies in this industry account for over 60% of the market share, of which, the US based Applied Materials and the Dutch giant ASM (70% share of the global mask aligner market) hold 19% and 17% global market shares respectively. On the other hand, numerous global giants have set up manufacturing bases in China in recent years, which enabled the domestic semiconductor equipment market to expand to US\$6.6bn as of 2015, accounting for over 15% of the global total. Over the past five years, the market in China has witnessed CAGR of 12.4%, far outstripping the global growth of 1.9%. Nevertheless, the domestic industry is still facing challenges. Despite the continued migration of the semiconductor industry to mainland China, constrained by technological limitations, domestic firms are yet to benefit substantially from this trend. In fact, market shares of domestic manufacturers have been on the decline over the recent years, putting urgency on Chinese companies to lift their game.
- Playing to each other's strengths with the acquisition of NMC. Sevenstar is China's top player in manufacturing of oxidation furnaces and wafer cleaning systems while NMC has leading technology in silicon etching, PVD and CVD equipment. In particular, the latter owns exclusive 28nm silicon etching and PVD technology in China. By



## **BUY** (Initial Coverage) Current price: Rmb24.55 Target price: Rmb29.50

# **CITICS Research**

### WANG Shaobo

Tel: 021-20262120 Email: wangshaobo@citics.com Practicing license: S1010513080005

# Performance relative to the index



Source: CITICS Quantitative Investment Analysis System

Main data	
CSI 300	3617.66
Total equity/shares o/s (mn)	337/352
LTM High/low (Rmb)	60.2/16.8
1-month absolute gain	-14.9%
6-month absolute gain	-33.53%
YTD Absolute gain	12.55%
LTM Average daily turnover (Rmb mn)	190.02



acquiring NMC, Sevenstar will expand its business coverage to the five major processes of manufacturing integrated circuits (wafer development, wafer cleaning, oxidation, etching and membrane deposition). Playing to each other's strengths, we anticipate leap-frog growth for Sevenstar going forward.

- Expected to replicate the AMAT's path to success and establish a semiconductor equipment manufacturing platform. The US based Applied Materials is the world's largest supplier of semiconductor equipment, which relied heavily on M&As (around nine major deals during its 30 years of rapid expansion) to bolster its product range throughout its development. We believe Sevenstar may replicate the development path of AMAT, which is also aligned with the government's intention of fostering 1-2 major players for China's semiconductor equipment industry amidst a fragmented domestic market at present. Over the long-term, we believe Sevenstar's domestic market share could progressively rise to 40% with revenue to exceed US\$2.0bn (~15x of its current level), enabling the Company to be ranked in the top-echelon of the semiconductor equipment industry.
- **Risks:** (i) business development falling short of expectations; (ii) disappointing technology R&D.
- Earnings forecast, valuation and investing rating. We forecast its 2016-17E EPS to be Rmb0.27/0.32. The stock is currently trading at Rmb24.55, implying 2016/17 P/E and P/B of 89/76x and 3.6/3.4x respectively. Due to the protracted R&D cycle and substantial investments involved in the production of semiconductor equipment, the acquisition of Beijing North Microelectronics is unlikely to give an immediate boost the Company's earnings. Nevertheless, it will not undermine Sevenstar's competitiveness and industry status. Within the A-share electronics sphere, semiconductor equipment manufacturers are highly sought after by investors thanks to their scarcity, while they are also expected to benefit extensively from favorable industry policies. Drawing reference from the development path of its peers, we are upbeat on the Company's long-term prospects as we believe it will focus on both organic and inorganic growth going forward. Initiate coverage with BUY and a target price of Rmb29.5 (4.3x P/B).

Item/Year	2013	2014	2015E	2016E	2017E
Turnover (Rmb mn)	859.5	961.7	854.5	1,533.4	1,890.4
Growth rate (YoY, %)	(15.1)	11.9	(11.2)	79.5	23.3
Net profit (Rmb mn)	103.1	41.9	38.6	125.8	148.3
Growth rate (YoY, %)	(27.0)	(59.4)	(7.9)	226.1	17.9
EPS (Fully diluted, Rmb)	0.29	0.12	0.11	0.27	0.32
EPS (Market consensus, Rmb)			0.11	0.29	0.45
Gross margin (%)	41.9	34.6	39.2	40.1	39.9
ROE (%)	5.5	2.2	1.9	4.9	4.6
PE (x)	84	206	224	89	76
PB (x)	4.5	4.4	4.2	3.6	3.4
EV/EBITDA (x)	53.7	60.5	81.7	(110.0)	275.5

Source: CITICS Quantitative Investment Analysis System Note: Closing price as of 18 Mar 2016

Income State	ment			(Rm	b mn)
Indicator	2013	2014	2015E	2016E	2017E
Turnover	860	962	854	1,533	1,890
Operating cost	499	629	520	918	1,136
Gross margin	41.9%	34.6%	39.2%	40.1%	39.9%
Business tax & surcharge	4	5	4	8	9
Selling expense	48	45	51	92	95
Selling expense ratio	5.6%	4.6%	6.0%	6.0%	5.0%
Administrative expense	160	179	222	690	699
Administrative expense ratio	18.7%	18.6%	26.0%	45.0%	37.0%
Financial expense	1	10	12	14	17
Financial expense ratio	0.1%	1.1%	1.4%	0.9%	0.9%
Investment revenue	9	38	0	0	0
Operating profit	137	57	45	-189	-65
Operating profit margin	16.0%	5.9%	5.3%	-12.3%	-3.5%
Non-operating income	23	45	51	380	280
Non-operating expenditure	1	1	0	0	0
Total profit	159	100	96	191	215
Income tax	27	27	26	33	36
Income tax rate	17.0%	26.6%	26.6%	17.0%	17.0%
Minority interests	29	32	32	33	30
Net profit attributable to shareholders of parent company	103	42	38.6	125.8	148.3
Net margin	12.0%	4.4%	4.5%	8.2%	7.8%

Balance Shee	et			(Rmb	mn)
Indicator	2013	2014	2015E	2016E	2017E
Cash and cash equivalents	263	213	162	480	320
Inventory	615	566	520	918	1,136
Accounts receivable	597	594	538	966	1,036
Other current assets	101	93	83	77	63
Current assets	1,576	1,466	1,303	2,441	2,554
Fixed assets	552	621	1,181	1,295	1,400
Long-term equity investment	0	0	0	0	0
Intangible assets	511	687	687	687	687
Other long-term assets	1,107	1,112	824	991	1,175
Non-current assets	2,170	2,420	2,693	2,973	3,263
Total assets	3,746	3,886	3,996	5,414	5,817
Short-term borrowing	117	195	209	266	295
Accounts payable	305	307	253	448	554
Other current liabilities	305	300	300	300	300
Current liabilities	727	801	762	1,014	1,149
long-term liabilities	0	0	0	0	0
Other long-term liabilities	1,093	1,121	1,199	1,283	1,373
Non-current liabilities	1,093	1,121	1,199	1,283	1,373
Total liabilities	1,820	1,922	1,961	2,297	2,522
Share capital	352	352	352	458	458
Capital reserve	1,472	1,479	1,518	2,462	2,610
Owner's equity	1,926	1,964	2,035	3,117	3,295
Minority interests	102	133	165	198	228
Liabilities & owner's equity	3,746	3,886	3,996	5,414	5,817

Cash Flow Statement (Rmb mn)					
Indicator	2013	2014	2015E	2016E	2017E
Pre-tax profit	159	100	96	191	215
Change in working capital	-27	-27	-26	-33	-36
Depreciation & amortization	44	68	71	79	88
Change in working capital	-219	-100	60	-626	-167
Others	17	51	-32	-33	-30
Operating cash flow	-26	93	169	-421	69
CAPEX	-166	-196	-159	-159	-159
Investment revenue	0	0	0	0	0
Disposal of assets	3	0	0	0	0
Others	-2	2	-184	-201	-219
Investing cash flow	-164	-194	-343	-360	-378
Stock issuance	0	0	0	924	0
Change in liabilities	-90	78	13	58	29
Dividend paid	-45	-27	0	0	0
Others	0	0	110	117	120
Financing cash flow	-135	51	124	1,098	149
Net increase in cash and equivalents	-326	-50	-51	318	-160

Main					
Financials	2013	2014	2015E	2016E	2017E
Growth (%)					
Turnover	-15.1	11.9	-11.2	79.5	23.3
Operating profit	-26.1	-58.9	-20.0	N.A.	N.A.
Net profit	-27.0	-59.4	-7.9	226.1	17.9
Margin (%)					
Gross margin	41.9	34.6	39.2	40.1	39.9
EBIT Margin	16.0	5.9	5.3	-12.3	-3.5
EBITDA Margin	22.1	17.8	15.0	-6.2	2.1
Net margin	15.4	7.6	8.2	10.4	9.4
Return (%)					
ROE	5.5	2.2	1.9	4.9	4.6
ROA	3.6	1.9	1.8	3.4	3.2
Others (%)					
Liability/asset ratio	48.6	49.5	49.1	42.4	43.3
Income tax rate	17.0	26.6	26.6	17.0	17.0
Dividend payout ratio	43.9	65.3	0.0	0.0	0.0

Source: Company announcement, CITICS Research forecast

Analyst Certification: The analysts primarily responsible for the preparation of all or part of the research report contained herein hereby certify that: (i) the views expressed in this research report accurately reflect the personal views of each such analyst about the subject securities and issuers; and (ii) no part of the analyst's compensation was, is, or will be directly or indirectly, related to the specific recommendations or views expressed in this research report.

### Investment rating system

Rating standard for Investment Recommendations		Ratings	Description
Investment ratings are divided into stock rating and sector rating (unless stated otherwise). Rating standard is based on the relative performance with market in 6 to 12 months from the report issuance date, i.e. Performance of company stock price (or sector index) over the 6-to-12-month period from report issuance day is benchmarked against the change in market representative index in the same period. CSI 300 Index will be the benchmark index for A-share market; the NEEQ Component	Stock ratings	BUY	Increase relative to market representative index over 20%
		OVERWEIGHT	Increase relative to market representative index between 5% and 20%
		HOLD	Increase relative to market representative index between -10% and 5%
		SELL	Decrease relative to market representative index over 10%
Index (stocks subject to negotiated transfer) or the NEEQ Market Making Index (stocks subject to market making) will be the benchmark index for the NNEQ board; MSCI-China Index will be	Industry	OUTPERFORM	Increase relative to market representative index over10%
the benchmark index for Hong Kong market; and NASDAQ Composite Index or Standard & Poor's 500 Index will be the benchmark indices for U.S. market.		NEUTRAL	Increase relative to market representative index between -10% and 10%
		UNDERPERFORM	Decrease relative to market representative index over 10%

### **Other Disclosures**

This research report has been prepared by CITIC Securities Company Limited ("CS") or an affiliate thereof. CS, its subsidiaries, branches and affiliates (excluding CLSA group of companies for the purpose of this research report disclaimer) are referred to herein as "CITIC Securities".

### Legal Entities Disclosures

China: This material is issued and distributed in the People's Republic of China (excluding Hong Kong, Macau and Taiwan) through CS (Securities Business License Number Z20374000) which is regulated by the China Securities and Regulatory Commission.

**Singapore:** This material is distributed in Singapore through CLSA Singapore Pte Limited ("CLSA Singapore") and may only be provided to Institutional Investors, Accredited Investors and Expert Investors, as defined in s.4A(1) of the Securities and Futures Act. Any such investor wishing to discuss this material or effect transactions in any security discussed herein should do so with or through MAS licensed representatives of CLSA Singapore. If you are an accredited investor or expert investor, please be informed that in CLSA Singapore's dealings with you, it is relying on certain exemptions to the Financial Advisers Act ("FAA") - (1) the exemption in Regulation 33 of the Financial Advisers Regulations ("FAR"), which exempts it from complying with Section 25 of the FAA on disclosure of product information to clients; (2) the exemption set out in Regulation 34 of the FAR, which exempts it from complying with Section 27 of the FAA on certain interests in securities.

### **Jurisdiction Specific Disclosures**

China: Businesses scope of CS includes securities investment advisory service, according to the securities business license issued by the China Securities Regulatory Commission.

Singapore: Regulations or exchange rules prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation and the full details are available at https://www.clsa.com/disclosures/. Disclosures therein include the position of CLSA group, CLSA Americas and CA Taiwan only and do not reflect those of CITIC Securities, Credit Agricole Corporate & Investment Bank and/or their respective affiliates. If investors have any difficulty accessing this website or require disclosure information on previous dates, please contact compliance\_hk@clsa.com.

United States: This research report has been produced in its entirety by CITIC Securities. This research report is distributed into the United States by CITIC Securities (excluding CITIC Securities International USA, LLC ("CSI-USA")) and CLSA group of companies (excluding CLSA Americas, LLC ("CLSA Americas")) solely to persons who qualify as "major U.S. institutional investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CSI-USA and CLSA Americas respectively. However, the delivery of this research report to any person in the United States shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research report from CITIC Security mentioned herein should do so by contacting CSI-USA and CLSA Americas respectively.

**United Kingdom:** The disclosures contained in this part of "United Kingdom" shall be governed by and interpreted in accordance with British law. This research is a marketing communication. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research as defined in the Financial Conduct Authority Handbook, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The research is disseminated in the EU by CLSA (UK), which is authorized and regulated by the Financial Conduct Authority. This document is directed at persons having professional experience in matters relating to investments as defined in Article 19 of the FSMA 2000 (Financial Promotion) Order 2005. Any investment activity to which it relates is only available to such persons. If you do not have professional experience in matters relating to investments you should not rely on this document.

### General

This research report is strictly confidential to the recipient and provided only for the use of the recipient and it is not intended for persons in places where the distribution or publication of this research report is not permitted under the applicable laws or regulations of such places. This research report is for information purposes only and should not be construed as an offer to buy or sell or the solicitation of an offer to buy or sell any securities or financial instruments in any jurisdiction. CITIC Securities will not deem the recipient as its clients by reason of their receiving this report. The opinions and recommendations herein do not take into account individual client circumstances, objectives or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make his own independent decisions regarding any securities or financial instruments mentioned herein.

Information has been obtained from sources believed to be reliable but CITIC Securities do not warrant its accuracy or completeness. CITIC Securities assumes no liability whatsoever for any direct or consequential loss arising from any use of material contained in this research report or otherwise arising in connection therewith. Any securities referred to herein may involve significant risk, may be illiquid and may not be suitable for all investors. The prices, values and income of the securities or financial instruments referred to herein may fluctuate and be affected by changes in exchange rates. Past performance is not indicative of future results.

Information, opinions and estimates contained herein reflect the judgment of analyst(s) of CITIC Securities at the date of its original publication and are subject to changes without notification. They also may be different from or contrary to the opinions presented by other business departments, units or affiliates of CITIC Securities, as different assumptions, standards, views and analytical methods may be adopted in the preparation of such other materials, and CITIC Securities has no obligation to bring such other materials to the attention of any recipient of this report. CITIC Securities relies on information barriers to control the flow of information contained in one or more areas within CITIC Securities, into other areas, units, groups or affiliates of CITIC Securities. The compensation of analysts who prepared this research report is determined solely by the management of Research Department and senior management of CITIC Securities. Analysts' compensation is not decided based on revenue of CITIC Securities' investment banking business but may be linked with overall revenue of its investment banking are a part.

If this research report is distributed by a financial institution other than CITIC Securities, that financial institution is solely responsible for its distribution. Clients of that institution should contact that institution to effect a transaction in the securities mentioned in this research report or if they require further information. This research report does not constitute investment advice by CITIC Securities to the clients of the distributing financial institution, and neither CITIC Securities nor its respective officers, directors and employees will accept any liability whatsoever for any direct or consequential loss arising from their use of this research report or its content.

This research report may not be reproduced, distributed or sold by any person for any purpose without the prior written consent of CITIC Securities. Copyright 2016.CITICSecurities. All rights reserved.